

Edward B Garon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/994458/publications.pdf>

Version: 2024-02-01

152
papers

33,766
citations

61984

43
h-index

12272

133
g-index

154
all docs

154
docs citations

154
times ranked

32512
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	12.6	6,756
2	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1540-1550.	13.7	5,456
3	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	27.0	5,183
4	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	27.0	4,701
5	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1998.	7.4	1,386
6	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <i>Lancet</i> , The, 2014, 384, 665-673.	13.7	1,068
7	Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. <i>Lancet Oncology</i> , The, 2017, 18, 895-903.	10.7	872
8	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	12.6	834
9	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	1.6	710
10	Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1700-1709.	27.0	615
11	Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 944-957.	27.0	542
12	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	7.1	446
13	A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1138-1145.	1.1	426
14	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	10.7	418
15	PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4349-4357.	1.6	326
16	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)., 2018, 6, 75.		188
17	In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. <i>International Journal of Cancer</i> , 2007, 121, 675-682.	5.1	165
18	Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. <i>Clinical Cancer Research</i> , 2018, 24, 5841-5849.	7.0	160

#	ARTICLE	IF	CITATIONS
19	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutationsâ€”The Lung Cancer Mutation Consortium (LCMC2). <i>Clinical Cancer Research</i> , 2018, 24, 1038-1047.	7.0	154
20	Phase I Trial of Intratumoral Injection of CCL21 Geneâ€”Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. <i>Clinical Cancer Research</i> , 2017, 23, 4556-4568.	7.0	149
21	Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 205-215.	1.1	149
22	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1â€”Positive Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1718-1732.	1.1	141
23	Development of transcriptomic biomarker signature in human saliva to detect lung cancer. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 3341-3350.	5.4	130
24	Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. <i>Cell Reports</i> , 2017, 18, 601-610.	6.4	125
25	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 387-397.	10.7	119
26	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitorâ€”related Pneumonitis. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e31-e43.	5.6	97
27	¹⁸ F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1684-1689.	5.0	94
28	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2016, 122, 766-772.	4.1	92
29	Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 443-452.	2.5	90
30	Uncertainty and psychological adjustment in patients with lung cancer. <i>Psycho-Oncology</i> , 2013, 22, 1396-1401.	2.3	89
31	Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1544-1555.	10.7	86
32	Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. <i>Scientific Reports</i> , 2018, 8, 2592.	3.3	81
33	Severity of COVID-19 in patients with lung cancer: evidence and challenges. , 2021, 9, e002266.		78
34	Inflammation and lung carcinogenesis: applying findings in prevention and treatment. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1405-1421.	2.4	71
35	Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. <i>Cancer Immunology Research</i> , 2018, 6, 288-294.	3.4	70
36	The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Nonâ€”Small Cell Lung Cancer Growth. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 890-900.	4.1	67

#	ARTICLE	IF	CITATIONS
37	Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. <i>Steroids</i> , 2011, 76, 910-20.	1.8	65
38	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 576-584.	1.1	62
39	Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5061-5068.	7.0	60
40	Identification of Common Predictive Markers of <i>In vitro</i> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non-Small Cell Lung Cancer Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1985-1994.	4.1	59
41	Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 270-278.	1.1	59
42	Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2015, 42, S11-S18.	2.2	55
43	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 793-801.	1.1	50
44	A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7275-7283.	2.0	49
45	Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis. <i>Oncologist</i> , 2015, 20, 224-226.	3.7	48
46	KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. <i>Journal of Clinical Oncology</i> , 2019, 37, 9013-9013.	1.6	42
47	Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. <i>Lung Cancer</i> , 2016, 93, 95-103.	2.0	41
48	Quantum dot labeling and tracking of human leukemic, bone marrow and cord blood cells. <i>Leukemia Research</i> , 2007, 31, 643-651.	0.8	40
49	A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design. <i>Clinical Lung Cancer</i> , 2012, 13, 505-509.	2.6	37
50	Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 123, 91-98.	2.0	35
51	Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients. <i>Frontiers in Oncology</i> , 2020, 10, 572895.	2.8	35
52	Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1618-1621.	1.1	32
53	Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). <i>Journal of Clinical Oncology</i> , 2016, 34, 9026-9026.	1.6	31
54	A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1284-1293.	1.1	30

#	ARTICLE	IF	CITATIONS
55	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. <i>Lung Cancer</i> , 2018, 120, 62-69.	2.0	29
56	Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7543-7543.	1.6	28
57	Defining comprehensive biomarker-related testing and treatment practices for advanced non-small cell lung cancer: Results of a survey of U.S. oncologists. <i>Cancer Medicine</i> , 2022, 11, 530-538.	2.8	28
58	The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 259-272.	1.5	27
59	KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS146-TPS146.	1.6	27
60	Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer. <i>Radiology</i> , 2018, 287, 326-332.	7.3	24
61	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5258-5271.	7.0	23
62	RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9000-9000.	1.6	23
63	Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. <i>Nature Cancer</i> , 2020, 1, 1167-1175.	13.2	22
64	Patient portal preferences: Perspectives on imaging information. <i>Journal of the Association for Information Science and Technology</i> , 2015, 66, 1606-1615.	2.9	20
65	Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11510-11510.	1.6	20
66	Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. <i>Cancer</i> , 2017, 123, 4800-4807.	4.1	19
67	The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 571.	7.1	18
68	Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 77-86.	2.3	18
69	Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2018, 19, e19-e28.	2.6	17
70	Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9521-9521.	1.6	17
71	Incidental Mediastinal Dose Does Not Explain Low Mediastinal Node Recurrence Rates in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiotherapy. <i>Clinical Lung Cancer</i> , 2014, 15, 287-293.	2.6	16
72	Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. <i>Nature Communications</i> , 2021, 12, 4172.	12.8	16

#	ARTICLE	IF	CITATIONS
73	Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9582-9582.	1.6	16
74	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
75	Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. Lung Cancer, 2012, 77, 475-481.	2.0	13
76	Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR -Mutant Metastatic Nonâ€“Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clinical Lung Cancer, 2018, 19, 213-220.e4.	2.6	13
77	A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 4566-4573.	7.0	13
78	A Prospective Phase 2 Study Evaluating Safety and Efficacy of Combining Stereotactic Body Radiation Therapy With Heat-based Ablation for Centrally Located Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2018, 101, 564-573.	0.8	12
79	First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 9051-9051.	1.6	12
80	Capmatinib in patients with high-level <i>MET</i>-amplified advanced nonâ€“small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.. Journal of Clinical Oncology, 2020, 38, 9509-9509.	1.6	12
81	Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9619-9619.	1.6	12
82	Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer, 2017, 112, 126-133.	2.0	11
83	Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer, 2017, 106, 76-82.	2.0	11
84	Management of common adverse events related to first-line dacomitinib use in <i>EGFR</i> mutation-positive non-small-cell lung cancer: a pooled safety analysis. Future Oncology, 2019, 15, 1481-1491.	2.4	11
85	Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated <i>EGFR</i>-mutated metastatic non-small-cell lung cancer. Current Medical Research and Opinion, 2020, 36, 1667-1675.	1.9	11
86	The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS9124-TPS9124.	1.6	11
87	Targeting MEK for the Treatment of Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, S377-S378.	1.1	10
88	Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 96-99.	2.6	10
89	Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review. Frontiers in Immunology, 2020, 11, 1036.	4.8	10
90	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Nonâ€“Small-Cell Lung Cancer (MYSTIC). Clinical Lung Cancer, 2021, 22, 301-312.e8.	2.6	10

#	ARTICLE	IF	CITATIONS
91	Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1-Positive NSCLC.. Journal of Clinical Oncology, 2016, 34, 9015-9015.	1.6	10
92	Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer. Lung Cancer, 2019, 131, 6-13.	2.0	9
93	Capmatinib in patients with <i>MET</i> 14-mutated or high-level <i>MET</i> -amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.. Journal of Clinical Oncology, 2020, 38, 9520-9520.	1.6	9
94	Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. Clinical Lung Cancer, 2018, 19, 270-279.e3.	2.6	8
95	Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. Lung Cancer, 2021, 155, 53-60.	2.0	8
96	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. ESMO Open, 2020, 5, e000567.	4.5	7
97	Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. Lung Cancer, 2021, 161, 34-41.	2.0	7
98	Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 200-208.	2.6	6
99	The race for combined checkpoint inhibition in NSCLC. Lancet Oncology, The, 2016, 17, 259-260.	10.7	6
100	REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.. Journal of Clinical Oncology, 2014, 32, LBA8006-LBA8006.	1.6	6
101	Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010.. Journal of Clinical Oncology, 2017, 35, 77-77.	1.6	6
102	CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS8570-TPS8570.	1.6	6
103	CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, TPS9075-TPS9075.	1.6	6
104	Estrogen Receptor- β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Critical Reviews in Oncogenesis, 2015, 20, 373-390.	0.4	6
105	Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come. Critical Reviews in Oncogenesis, 2015, 20, 339-347.	0.4	6
106	RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. Drug Safety, 2022, 45, 45-64.	3.2	6
107	Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study. Translational Lung Cancer Research, 2017, 6, S39-S40.	2.8	5
108	The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC. Journal of Thoracic Oncology, 2018, 13, 1058-1059.	1.1	5

#	ARTICLE	IF	CITATIONS
109	Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 135, 104-109.	2.0	5
110	457â€¦KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for nonâ€“small cell lung cancer (NSCLC). , 2021, 9, A485-A485.		5
111	Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL. <i>Lung Cancer</i> , 2021, 151, 25-29.	2.0	4
112	Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3030-3030.	1.6	4
113	Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9104-TPS9104.	1.6	4
114	<i>cfTrack</i>: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. <i>Clinical Cancer Research</i> , 2022, 28, 1841-1853.	7.0	4
115	ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. <i>European Journal of Cancer</i> , 2022, 166, 112-125.	2.8	4
116	RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposureâ€“response relationship. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 137-148.	2.3	4
117	Abstract 24: Multi-feature ensemble learning on cell-free dna for accurately detecting and locating cancer. <i>Cancer Research</i> , 2021, 81, 24-24.	0.9	3
118	Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal study.. <i>Health Psychology</i> , 2022, 41, 301-310.	1.6	3
119	Mitotic Inhibitors. <i>Journal of Thoracic Oncology</i> , 2011, 6, S1791-S1792.	1.1	2
120	Torsades de pointes with pseudoâ€“T wave alternans during rociletinib therapy: A novel manifestation of a rare side effect. <i>HeartRhythm Case Reports</i> , 2018, 4, 490-493.	0.4	2
121	Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 195-197.	2.8	2
122	KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit. <i>Translational Lung Cancer Research</i> , 2019, 8, S403-S406.	2.8	2
123	Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study. <i>Supportive Care in Cancer</i> , 2021, 29, 117-125.	2.2	2
124	Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100150.	1.1	2
125	Osimertinib plus Ramucirumab: The Best of Both Worlds?. <i>Clinical Cancer Research</i> , 2021, 27, 905-907.	7.0	2
126	Patient-reported outcomes from POINTBREAK: The randomized, open-label, phase III study of pemetrexed (pem) + carboplatin (cb) + bevacizumab (bev) followed by maintenance pem + bev versus paclitaxel (pac) + cb + bev followed by maintenance bev in patients with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 53-53.	1.6	2

#	ARTICLE	IF	CITATIONS
127	Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.. Journal of Clinical Oncology, 2019, 37, 9048-9048.	1.6	2
128	RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9564-9564.	1.6	2
129	Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non-“Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies. Clinical Lung Cancer, 2022, 23, 253-263.	2.6	2
130	Are lung adenocarcinoma mutations shaping the immune microenvironment?. Translational Cancer Research, 2018, 7, S740-S742.	1.0	2
131	Poly(ADP-Ribose) Polymerase Inhibitors. Journal of Thoracic Oncology, 2010, 5, S455-S456.	1.1	1
132	Toward patient-tailored summarization of lung cancer literature. , 2016, 2016, 449-452.		1
133	High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studies. Journal of Thoracic Disease, 2018, 10, S397-S403.	1.4	1
134	A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06).. Journal of Clinical Oncology, 2020, 38, TPS9084-TPS9084.	1.6	1
135	Randomized phase III trial of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance Pem+Bev (Pem arm) versus paclitaxel (Pac)+Cb+Bev followed by maintenance Bev (Pac arm) in patients (pts) with stage IIIb/IV nonsquamous non-small cell lung cancer (nsNSCLC) (POINTBREAK): African American (AA) subset.. Journal of Clinical Oncology. 2013, 31, e19150-e19150.	1.6	1
136	Pemetrexed (Pem) with pembrolizumab (Pembro) maintenance: A post hoc subgroup safety analysis of KEYNOTE-189.. Journal of Clinical Oncology, 2020, 38, 51-51.	1.6	1
137	RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).. Journal of Clinical Oncology, 2020, 38, 9527-9527.	1.6	1
138	Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story. Journal of Thoracic Oncology, 2019, 14, 160-162.	1.1	0
139	Is there hope in improving 5-year overall survival?â€”review of 5-year overall survival data from KEYNOTE-001. Annals of Translational Medicine, 2020, 8, 728-728.	1.7	0
140	Utility of Quantum Dots for Labeling and Tracking Leukemic Cell Lines, Human Bone Marrow and CD 34+ Umbilical Cord Blood.. Blood, 2005, 106, 1729-1729.	1.4	0
141	Effects of FDA drug approvals on a thoracic oncology programâ€™s clinical trial enrollment in 2015.. Journal of Clinical Oncology, 2016, 34, e20662-e20662.	1.6	0
142	Electrostatic human leukocyte antigen-neoantigen interactions and durable benefit in non-small cell lung cancer patients treated with immunotherapy.. Journal of Clinical Oncology, 2019, 37, 2635-2635.	1.6	0
143	Prevalence of human leukocyte antigen-B27 supertype in the context of positively charged neoepitopes and association with PD-L1 as an immune escape mechanism.. Journal of Clinical Oncology, 2020, 38, 3083-3083.	1.6	0
144	SUN-125 Phase Ib Study of Dual Therapy with an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women with Advanced Non-Small Cell Lung Cancer. Journal of the Endocrine Society, 2020, 4, .	0.2	0

#	ARTICLE	IF	CITATIONS
145	390â€¦A global, molecular disease characterization initiative (MDCI) in oncology clinical trials. , 2021, 9, A423-A423.		0
146	Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC. Med, 2021, 2, 1201-1202.	4.4	0
147	364â€¦KRAS mutations in patients with nonsquamous nonâ€œsmall-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status. , 2021, 9, A391-A391.		0
148	What is the current role of immunotherapy in EGFR mutant advanced NSCLC?. Lung Cancer, 2021, , .	2.0	0
149	Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC. , 0, , .		0
150	Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.. Journal of Clinical Oncology, 2022, 40, 9035-9035.	1.6	0
151	Circulating tumor DNA (ctDNA) mutations associate with response in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib (TALA) and temozolomide (TMZ).. Journal of Clinical Oncology, 2022, 40, 8582-8582.	1.6	0
152	Cost of consent document (CD) translation is a potential barrier to consenting limited English-proficient participants (LEPPs) in non-industryâ€œsponsored studies (NISS).. Journal of Clinical Oncology, 2022, 40, 6533-6533.	1.6	0